A Cross-Sectional Study Assessing Appropriateness Of Inhaled Corticosteroid Treatment In Primary And Secondary Care Patients With COPD In Sweden

References

• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–582. doi:10.1164/rccm.201701-0218PP28128970
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374(23):2222–2234. doi:10.1056/NEJMoa151638527181606
   PubMed Web of Science ®Google Scholar
• Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):1285–1294. doi:10.1056/NEJMoa140715425196117
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa171390129668352
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Tebboth A, Gayle A, Ternouth A, Ramscar N. Determinants of initial inhaled corticosteroid use in patients with GOLD A/B COPD: a retrospective study of UK general practice. NPJ Prim Care Respir Med. 2017;27(1):43. doi:10.1038/s41533-017-0040-z28663549
   PubMed Web of Science ®Google Scholar
• Sundh J, Aberg J, Hasselgren M, et al. Factors influencing pharmacological treatment in COPD: a comparison of 2005 and 2014. Eur Clin Respir J. 2017;4(1). doi:10.1080/20018525.2017.1409060
   Web of Science ®Google Scholar
• Casas A, Montes de Oca M, Menezes AM, et al. Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study. Int J Chron Obstruct Pulmon Dis. 2018;13:1545–1556. doi:10.2147/COPD.S15409729785104
   PubMed Web of Science ®Google Scholar
• Kaplan AG. Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practice. Int J Chron Obstruct Pulmon Dis. 2015;10:2535–2548. doi:10.2147/COPD.S9332126648711
   PubMed Web of Science ®Google Scholar
• International Primary Care Respiratory Group (IPCRG). Evaluation of appropriateness of inhaled corticosteroid (ICS) therapy in COPD and guidance on ICS withdrawal. March–July 2018 Available from: https://www.theipcrg.org/ Accessed 1017, 2019.
   Google Scholar
• Högman M, Sulku J, Ställberg B, et al. 2017 global initiative for chronic obstructive lung disease reclassifies half of COPD subjects to lower risk group. Int J Chron Obstruct Pulmon Dis. 2018;13:165–173. doi:10.2147/COPD.S15101629379281
   PubMed Web of Science ®Google Scholar
• Guo Y, Zhang T, Wang Z, et al. Body mass index and mortality in chronic obstructive pulmonary disease: a dose-response meta-analysis. Medicine. 2016;95(28). doi:10.1097/MD.0000000000004225
   Web of Science ®Google Scholar
• The National Board of Health and Welfare (Socialstyrelsen). Nationella riktlinjer för vård vid astma och KOL. 2018 Available from: http://www.socialstyrelsen.se/ Accessed 1017, 2019.
   Google Scholar
• Hedenstrom H, Malmberg P, Agarwal K. Reference values for lung function tests in females. Regression equations with smoking variables. Bull Eur Physiopathol Respir. 1985;21(6):551–557.4074961
   PubMedGoogle Scholar
• Hedenstrom H, Malmberg P, Fridriksson HV. Reference values for lung function tests in men: regression equations with smoking variables. Ups J Med Sci. 1986;91(3):299–310. doi:10.3109/030097386091786703811032
   PubMed Web of Science ®Google Scholar
• Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(4):347–365. doi:10.1164/rccm.201204-0596PP22878278
   PubMed Web of Science ®Google Scholar
• Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34(3):648–654. doi:10.1183/09031936.0010250919720809
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Bestall JC, Garrod R, Garnham R, Paul EA, Jones PW. Randomized controlled trial of pulmonary rehabilitation in severe chronic obstructive pulmonary disease patients, stratified with the MRC dyspnoea scale. Eur Respir J. 1998;12(2):363–369. doi:10.1183/09031936.98.120203639727786
   PubMed Web of Science ®Google Scholar
• Mahler DA, Rosiello RA, Harver A, Lentine T, McGovern JF, Daubenspeck JA. Comparison of clinical dyspnea ratings and psychophysical measurements of respiratory sensation in obstructive airway disease. Am Rev Respir Dis. 1987;135(6):1229–1233. doi:10.1164/arrd.1987.135.6.12293592398
   PubMed Web of Science ®Google Scholar
• Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000;117(5Suppl 2):398s–401s. doi:10.1378/chest.117.5_suppl_2.398S10843984
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis management, and prevention of chronic obstructive pulmonary disease. 2019 Available from: https://goldcopd.org/ Accessed 1017, 2019.
   Google Scholar
• Ismaila AS, Birk R, Shah D, et al. Once-daily triple therapy in patients with advanced COPD: healthcare resource utilization data and associated costs from the FULFIL trial. Adv Ther. 2017;34(9):2163–2172. doi:10.1007/s12325-017-0604-x28875459
   PubMed Web of Science ®Google Scholar
• Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6(2):117–126. doi:10.1016/S2213-2600(18)30006-729331313
   PubMed Web of Science ®Google Scholar
• Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018. doi:10.1016/S0140-6736(18)30206-X
   Web of Science ®Google Scholar
• Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017;389(10082):1919–1929. doi:10.1016/S0140-6736(17)30188-528385353
   PubMed Web of Science ®Google Scholar
• Swedish Medical Products Agency (Läkemedelsverket). Kroniskt obstruktiv lungsjukdom (KOL) behandlingsrekommendation. 2015 Available from: https://lakemedelsverket.se/ Accessed 1017, 2019.
   Google Scholar
• Siddiqui SH, Guasconi A, Vestbo J, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192(4):523–525. doi:10.1164/rccm.201502-0235LE26051430
   PubMed Web of Science ®Google Scholar
• Swedish Medical Products Agency (Läkemedelsverket). Farmakologisk behandling av kroniskt obstruktiv lungsjukdom – KOL. 2009 Available from: https://lakemedelsverket.se/ Accessed 1017, 2019.
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD. 2014 Available from: https://goldcopd.org/ Accessed 1017, 2019.
   Google Scholar
• Thomas M, Radwan A, Stonham C, Marshall S. COPD exacerbation frequency, pharmacotherapy and resource use: an observational study in UK primary care. Copd. 2014;11(3):300–309. doi:10.3109/15412555.2013.84167124152210
   PubMedGoogle Scholar
• Roman-Rodriguez M, van Boven JF, Vargas F, et al. Factors associated with inhaled corticosteroids prescription in primary care patients with COPD: a cross-sectional study in the Balearic Islands (Spain). Eur J Gen Pract. 2016;22(4):232–239. doi:10.1080/13814788.2016.121201127597172
   PubMed Web of Science ®Google Scholar
• Roche N, Chapman KR, Vogelmeier CF, et al. Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment. data from the FLAME trial. Am J Respir Crit Care Med. 2017;195(9):1189–1197. doi:10.1164/rccm.201701-0193OC28278391
   PubMed Web of Science ®Google Scholar